

LRRC15 Recombinant Monoclonal Antibody [BLR356N]

Rabbit Recombinant Monoclonal

Purified		RefSeq ID	NP_570843.2
Catalog No.	A700-356	Uniprot ID	Q8TF66
Lot No.	1	GeneID	131578

APPLICATIONS	WB, IP, IHC, ICC
SPECIES REACTIVITY	Human
AMOUNT	100 µl (50+ tests)
CONCENTRATION	250 µg/ml
STORAGE/SHELF LIFE	2 – 8°C / 1 year from date of receipt
PHYSICAL STATE	Liquid
BUFFER	Phosphate Buffered Saline (PBS) with 0.1% BSA and 0.09% Sodium Azide
ISOTYPE	IgG
CLONE #	BLR356N
ORIGIN	USA
PRODUCTION PROCEDURES	Recombinant antibody was purified from cell culture supernatant. Immunogen was a recombinant protein representing human Leucine-rich repeat-containing protein 15 (LRRC15, residues 22–538, NP_570843.2).
APPLICATIONS	Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use. Western Blot 1:1,000 Immunoprecipitation 20 µl/mg lysate Immunohistochemistry 1:100 to 1:500. Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections. Immunocytochemistry 1:100 to 1:500. Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE cell sections.
APPLICATION NOTES	All western blot analysis is performed using 5% Milk-TBST for blocking and as antibody diluent. Primary antibody is incubated overnight. Western blots of cell lysates are performed using Goat anti-Rabbit IgG Heavy and Light Chain Antibody (A120-101P). Western blots of immunoprecipitates are performed using Goat anti-Rabbit Light Chain HRP Conjugate (A120-113P) with 5% Normal Pig Serum (S100-020) added to the blocking buffer.
IHC HUMAN CONTROLS	Breast Carcinoma, Colon Carcinoma, Metastatic Lymph Node, Osteosarcoma, A-172 Cells, IMR-90 Cells, SNB-75 Cells
IHC MOUSE CONTROLS	4T1 Cells
ADDITIONAL INFO	https://www.fortislifesciences.com/p/A700-356 Use the link above to view SDS, a current list of citations, and other product specific information.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.
Michael Spencer, PhD Date: February 24, 2025